Buy Accrufer (ferric maltol) Online For Sale
DISEASE INDICATIONS: Iron deficiency
MANUFACTURER: Shield Therapeutics
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Accrufer, also known as ferric maltol, is a prescription medication that supplies the body with iron to treat iron deficiency in adults with or without anemia.
Accrufer, also known as ferric maltol, is a medication used to treat iron deficiency in adults with or without anemia. Iron deficiency is a common health issue, particularly in women of childbearing age. It can be caused by inadequate dietary intake, chronic blood loss, or underlying medical conditions that hinder iron absorption. If left untreated, iron deficiency can manifest as anemia, resulting in reduced oxygen transportation, fatigue, and other health issues.
Accrufer works by supplying the body with the required amount of iron to correct iron deficiency and increase hemoglobin production. The drug is taken orally and has been shown to be an effective treatment in clinical studies. Recent advancements in iron preparations have made it possible to administer iron in smaller doses with a better safety profile.
The European Medicines Agency (EMA) approved Accrufer in February 2016 under the name Feraccru (ferric maltol). The approval was based on clinical research that showed the drug’s effectiveness in alleviating iron deficiency anemia in adults. Ferric maltol is a type of oral iron salt taken with meals, which provides an alternative to intravenous iron therapy.
Accrufer functions by increasing the concentration of ferric iron in the blood, which helps to rebuild hemoglobin. Hemoglobin is responsible for transporting oxygen through the body, and the iron molecule in hemoglobin is required for this process to occur. Accrufer, like other iron supplements, can take several weeks for the effects to be noticeable.
Accrufer has been found to be well-tolerated by patients, with only minor side effects reported. The most common side effects of Accrufer include gastrointestinal issues such as nausea, vomiting, abdominal pain, and diarrhea. In rare cases, patients may experience more severe side effects such as anaphylaxis, which is a severe allergic reaction.
The use of Accrufer is not recommended in patients with iron overload disorders, such as hemochromatosis or iron storage disease. Accrufer is also contraindicated in individuals with anemia not associated with iron deficiency or a history of hypersensitivity to any of the drug’s components.
In conclusion, Accrufer is a potent medication that can effectively treat iron deficiency, with or without anemia, in adults. The medication is well-tolerated by patients and has minor side effects. It has been approved by the EMA under the name Feraccru for the European market. However, as with any medication, Accrufer should be taken only under a physician’s supervision to ensure the best outcomes for patients.
56 capsules of 30 mg